“The Niagen Research Program reflects both the maturity of the science and the scale of the global research community advancing it,” said Rob Fried, CEO of Niagen Bioscience. “For decades, we have focused on building the scientific foundation for NAD+ research through rigorous collaboration with leading independent investigators. As interest in NAD+ continues to grow, we believe credible science, clinical rigor, and responsible communication matter more than ever.”
Through the Niagen Research Program, independent investigators from world-renowned institutions such as Mayo Clinic, National Institutes of Health (NIH), Harvard University, MIT, and Cambridge University have historically requested Niagen for their pre-clinical and clinical research on NAD+ biology. The program provides oral food-grade and pharmaceutical-grade Niagen research materials, scientific collaboration, and technical support. There are 45+ peer-reviewed published clinical studies on Niagen to date, over 90% of which are completely independent.
Research conducted through the program has explored the roles of NAD+ and Niagen across clinically relevant tissues and organ systems, including skeletal and brain tissues, as well as cellular energy metabolism, cardiovascular health, inflammation, cognitive function, reproductive health, exercise performance, sleep quality, and agricultural applications. The program introduced emerging areas, including Peripheral Artery Disease and Ataxia Telangiectasia, a rare orphan disease, to the NAD+ research space. Further, recent research incorporated pharmaceutical-grade Niagen in clinical studies exploring IV and injectable administration. Currently, the program supports more than 175 ongoing and developing research studies.
In addition, the Company recently initiated the Niagen Bioscience Trainee Grant Program, which will award three $10,000 grants to graduate students and postdoctoral trainees pursuing investigator-initiated research for this year’s focus on exercise performance, recovery, fatigue, and adaptation, reflecting the Company’s commitment to supporting the next generation of NAD+ scientists.
The Niagen Research Program website also introduces an updated application and review process designed to support researchers pursuing studies involving both oral food-grade and pharmaceutical-grade Niagen materials.
- Dermatologic and cosmetic science
- Cognitive function
- Cellular energy metabolism
- Cardiovascular health
- Immune response and inflammation
- Exercise and muscle performance
- Reproductive health
- Sleep quality
- Pharmaceutical-grade injectable and intravenous Niagen
About Niagen Bioscience:
Niagen Bioscience, Inc. is the global authority in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.
For more information please visit, www.niagen-biosciences.com
